Science Overview2019-07-03T22:15:28+00:00
INVIVOSCRIBE

Science Overview

INVIVOSCRIBE

Science
Overview

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Invivoscribe is committed to improving the quality of healthcare worldwide, providing high quality, reliable, cutting-edge tools for molecular diagnostics and personalized molecular medicine.

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Invivoscribe is committed to improving the quality of healthcare worldwide, providing high quality, reliable, cutting-edge tools for molecular diagnostics and personalized molecular medicine.

Pushing the limits of diagnostic solutions for all hematologic diseases.

The fields of precision and personalized molecular diagnostics are rapidly gaining wide acceptance. A cooperative approach between drug manufactures and molecular diagnostic tools is guiding drug development and enabling tailored treatments.

The fields of precision and personalized molecular diagnostics are rapidly gaining wide acceptance. A cooperative approach between drug manufactures and molecular diagnostic tools is guiding drug development and enabling tailored treatments. Biomarker testing is frequently used to stratify and monitor patients, aid in treatment decisions, and identify targeted therapies. This is especially true in hematology and oncology, becoming the new paradigm and Standard of Care. The Invivoscribe LeukoStrat® CDx FLT3 Mutation test is fulfilling the promise of personalized molecular medicine: helping clinicians make informed treatment decisions with their patients; helping accelerate drug development; and lowering the cost of healthcare.

Molecular diagnostics demonstrate a potential to achieve many of the promises of personalized medicine, perhaps even controlling escalating healthcare costs. As the field matures and evolves, we are confident that molecular techniques will help predict disease, and when combined with patient education, will lead to earlier intervention and more emphasis on preventive medicine.

Pushing the limits of diagnostic solutions for all hematologic diseases.

The fields of precision and personalized molecular diagnostics are rapidly gaining wide acceptance. A cooperative approach between drug manufactures and molecular diagnostic tools is guiding drug development and enabling tailored treatments.

The fields of precision and personalized molecular diagnostics are rapidly gaining wide acceptance. A cooperative approach between drug manufactures and molecular diagnostic tools is guiding drug development and enabling tailored treatments. Biomarker testing is frequently used to stratify and monitor patients, aid in treatment decisions, and identify targeted therapies. This is especially true in hematology and oncology, becoming the new paradigm and Standard of Care. The Invivoscribe LeukoStrat® CDx FLT3 Mutation test is fulfilling the promise of personalized molecular medicine: helping clinicians make informed treatment decisions with their patients; helping accelerate drug development; and lowering the cost of healthcare.

Molecular diagnostics demonstrate a potential to achieve many of the promises of personalized medicine, perhaps even controlling escalating healthcare costs. As the field matures and evolves, we are confident that molecular techniques will help predict disease, and when combined with patient education, will lead to earlier intervention and more emphasis on preventive medicine.

Our innovations are based on challenging scientific questions. Our research and scientific collaborations back the development of cutting-edge hematologic diagnostics.

20-30% of patients with acute myeloid leukemia have mutations of the FLT3 biomarker that make them eligible for several FLT3-targeted small molecule therapies currently in late stage clinical trials.

Interim results indicate that FLT3-targeted drugs may improve survival and “obviate the need for allogeneic stem cell transplantation” (Reference: NCBI). If these results are confirmed, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease). Accordingly, the companion diagnostic FLT3 diagnostic test will provide access to a FLT3 small molecular inhibitor, which could result in improved survival coupled with cost savings of tens of thousands of dollars per AML patient. As there are more than thirty thousand new AML patients identified each year, this could result in hundreds of millions of dollars per year in potential cost savings. Further, these targeted therapies generally have substantively reduced side effects relative to those of standard chemotherapy, so the quality of life for the patient is potentially much improved.

Our innovations are based on challenging scientific questions. Our research and scientific collaborations back the development of cutting-edge hematologic diagnostics.

20-30% of patients with acute myeloid leukemia have mutations of the FLT3 biomarker that make them eligible for several FLT3-targeted small molecule therapies currently in late stage clinical trials.

Interim results indicate that FLT3-targeted drugs may improve survival and “obviate the need for allogeneic stem cell transplantation” (Reference: NCBI). If these results are confirmed, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease). Accordingly, the companion diagnostic FLT3 diagnostic test will provide access to a FLT3 small molecular inhibitor, which could result in improved survival coupled with cost savings of tens of thousands of dollars per AML patient. As there are more than thirty thousand new AML patients identified each year, this could result in hundreds of millions of dollars per year in potential cost savings. Further, these targeted therapies generally have substantively reduced side effects relative to those of standard chemotherapy, so the quality of life for the patient is potentially much improved.

We reach across three continents to develop harmonized resources to ensure the utmost in reliable and reproducible results.

Invivoscribe has invested substantial resources – capital equipment, research and development, intellectual property, regulatory and standardization processes.

Invivoscribe has invested substantial resources – capital equipment, research and development, intellectual property, regulatory and standardization processes, to ensure that we can completely investigate and understand the changes that occur in biomarkers at the molecular level in response to drug treatment and therapy. Targeted identification of specific biomarkers is critical for patient management, to control costs, and to provide the right drug, to the right patient, at the right dose, at the right time.

We reach across three continents to develop harmonized resources to ensure the utmost in reliable and reproducible results.

Invivoscribe has invested substantial resources – capital equipment, research and development, intellectual property, regulatory and standardization processes.

Invivoscribe has invested substantial resources – capital equipment, research and development, intellectual property, regulatory and standardization processes, to ensure that we can completely investigate and understand the changes that occur in biomarkers at the molecular level in response to drug treatment and therapy. Targeted identification of specific biomarkers is critical for patient management, to control costs, and to provide the right drug, to the right patient, at the right dose, at the right time.